Testagen
A short Khavinson-class peptide bioregulator derived from testicular tissue, researched for age-related decline in testosterone production and male reproductive function.
Testagen is a short synthetic peptide bioregulator developed in Vladimir Khavinson's laboratory at the Saint Petersburg Institute of Bioregulation and Gerontology and marketed in Russia as an oral capsule for male reproductive support. It is positioned as the testicular-specific member of the Khavinson short-peptide family (the male counterpart to Ovagen), proposed to enter cell nuclei in the testes and modulate age-related gene expression in Leydig cells, Sertoli cells, and the hypothalamic-pituitary-gonadal axis. All human evidence comes from a small, largely Russian-language body of Khavinson-group work with limited independent replication; Testagen has no Western regulatory approval and is sold as a research compound.
Class
Synthetic short-peptide bioregulator (Khavinson class); reported as a tetrapeptide (Lys-Glu-Asp-Phe) by some sources and a tripeptide (Lys-Glu-Asp) by others
Routes
Oral (capsule), Subcutaneous (research-chemical form)
Category
Longevity & Bioregulators
Researched benefits
What it's studied for
Testosterone production support
Proposed to support endogenous testosterone biosynthesis by acting on testicular Leydig cells rather than supplying exogenous hormone. Small open-label Khavinson-group observations suggest a modest ~15-30% rise in total testosterone from baseline in older men with subclinical or borderline-low levels; this is a weak signal relative to standard TRT.
Leydig cell function
Investigated for maintenance and restoration of Leydig cell activity, the cells responsible for testosterone synthesis, which decline with male aging. Effects are proposed to occur through epigenetic gene-expression regulation in preclinical rodent and cell models.
Spermatogenesis and Sertoli cell support
Claimed to support Sertoli-cell function and spermatogenesis. Khavinson-group data include modest and inconsistent observations of improved semen parameters; these are not randomized controlled trials and the effect is not established at Western clinical standards.
Age-related reproductive decline
Positioned as an adjunct for the age-associated decline in testicular function and reproductive hormones in men in their 40s-60s, proposed to nudge age-downregulated gene expression back toward a younger pattern.
Testicular tissue architecture
Preclinical bioregulator research has examined preservation of testicular histomorphology and gonadal markers with aging, consistent with the broader Khavinson tissue-specific bioregulator model.
Mechanism
How it works
Testagen is described within Vladimir Khavinson's short-peptide bioregulator framework, which posits that very short (2-4 residue) tissue-derived peptides can cross the gut wall and cell membranes passively, migrate preferentially to a specific target organ, enter cell nuclei, and bind sequence-selectively to regions of DNA associated with that tissue's developmental and housekeeping programs. In this model Testagen is the testicular-specific member of the family, said to restore expression of age-downregulated genes and partially reverse organ-level functional decline.
The proposed cellular targets are the Leydig cells (which produce testosterone), the Sertoli cells (which support spermatogenesis), and the spermatogonial lineage, with secondary action on hypothalamic GnRH neurons and pituitary gonadotropes of the hypothalamic-pituitary-gonadal (HPG) axis. Unlike testosterone replacement, the effect is framed as epigenetic regulation of endogenous steroidogenesis rather than direct hormone supplementation.
Whether this tissue-selective distribution and sequence-selective DNA binding occurs to a meaningful degree in humans is not settled in Western literature. The supporting pharmacokinetic and mechanistic studies are mostly from Khavinson's own group in cell culture or rodent models, and the human trials are small, single-center, open-label, and short. A notable structural complication is that some sources report Testagen as sharing the identical Lys-Glu-Asp tripeptide sequence with Vesugen (a bioregulator marketed for vascular tissue), while others report Testagen as a Lys-Glu-Asp-Phe tetrapeptide; where the sequences overlap, mass spectrometry alone cannot distinguish the two compounds, and the framework attributes their different proposed tissue targets to context-dependent effects rather than sequence differences.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
The commercial Khavinson product is an oral capsule and requires no reconstitution — it is swallowed whole with water on an empty stomach; the capsule should not be chewed or opened because the excipient matrix is designed for intact gut delivery. A separate research-chemical injectable form arrives as lyophilized powder, typically a 10 mg vial. Reconstituting a 10 mg vial with 2 mL bacteriostatic water yields 5 mg/mL (5000 mcg/mL), so a 100 mcg dose is 0.02 mL (2 units on a U-100 insulin syringe) and 200 mcg is 0.04 mL (4 units). Trickle the water down the vial wall, swirl gently (do not shake), and store reconstituted solution refrigerated at 2-8 C, using within 14-30 days.
Beginner
- Dose
- 1 capsule (20 mg nominal, ~2-4 mg peptide)
- Frequency
- Once daily
- Timing
- Morning, empty stomach, ~15-30 min before food
- Duration
- 10 consecutive days, then 60-90 day washout
- Route
- Oral
Reserved for confirmed subclinical low testosterone (~300-450 ng/dL with symptoms) in men who have declined formal therapy. Run solo (no TRT/SERM/hCG), keep a daily symptom log, and retest labs 30-45 days post-cycle. Limit to two cycles in the first year.
Intermediate
- Dose
- 2 capsules (40 mg nominal, ~4-8 mg peptide)
- Frequency
- Daily, split morning and early afternoon
- Timing
- Empty stomach
- Duration
- 10 consecutive days, then 60-90 day washout; up to 3 cycles/year
- Route
- Oral
For men who tolerated a prior cycle and are working with a clinician. May layer a single additional Khavinson peptide per cycle (e.g. Thymogen, Pinealon, or Epitalon) as experimental axis support. Monitor labs every 6 months including PSA; watch for PSA drift.
Advanced
- Dose
- 2-3 capsules (40-60 mg nominal, ~4-12 mg peptide)
- Frequency
- Daily, split morning and afternoon
- Timing
- Empty stomach
- Duration
- 10 consecutive days, then 60-90 day washout; up to 4 cycles/year
- Route
- Oral
Only for experienced users with stable labs and clinician oversight; incremental benefit over intermediate is small. Some rotate a 3-4 peptide Khavinson stack per cycle (n=1 experimentation). Monitor labs every 3-4 months. Not recommended for most men.
Injectable (research-chemical)
- Dose
- 50-200 mcg
- Frequency
- Once daily
- Timing
- Morning
- Duration
- 10-20 day cycle
- Route
- Subcutaneous (abdomen or thigh)
A research-chemical formulation distinct from the commercial capsule; much less studied, with added risks from sterile technique and dose uncertainty. The conservative recommendation is to use the oral capsule if any Testagen is used at all.
- The '20 mg capsule' label refers to total blended powder, not peptide dose — only ~2-4 mg per capsule is synthetic peptide, the balance being milk-protein isolate, starch, and other excipients.
- Cycling convention is 10-days-on / 60-to-90-days-off, typically 2-4 cycles per year (commonly spring and autumn). This is a Khavinson tradition, not a pharmacokinetically validated schedule — no data compare it to longer or continuous dosing.
- There is no dose-ranging data above 2 capsules daily; higher oral doses show no consistent added benefit, likely limited by absorption and first-pass metabolism.
- For fertility goals, spermatogenesis takes ~74 days, so any semen-parameter change requires at least 3 months (ideally 6 months with repeat analyses) to assess; a 10-day cycle aligns only loosely with that biology.
- Do not use while actively trying to conceive without a reproductive urologist, and do not layer onto TRT, clomiphene, enclomiphene, or hCG in early cycles — those interactions are poorly characterized and often redundant.
- Establish baseline labs (total and free testosterone, estradiol, LH, FSH, PSA if age 45+, CBC, CMP) before starting and plan ongoing monitoring.
Evidence
Research & clinical studies (2)
Open-label observations of short-peptide bioregulators on testosterone in aging men (Anisimov & Khavinson)
Referenced as small single-center open-label observations suggesting a modest ~15-30% rise in total testosterone from baseline in older men with borderline-low levels, without placebo control.
Peptides and Ageing / Khavinson bioregulator framework (Khavinson)
Describes the Khavinson model in which short peptides migrate preferentially to specific tissues, enter nuclei, and modulate gene expression in a tissue-selective manner, the framework underlying Testagen's proposed testicular action.
Combinations
Stacking & blends
Khavinson HPG axis rotation
Broad reproductive and immune axis support
Intermediate users pair Testagen with a single additional Khavinson peptide per cycle; Thymogen (immune) is a common partner. Running two bioregulators simultaneously is experimental and not supported by trial evidence.
Bioregulator longevity pairing
Reproductive support alongside pineal/circadian regulation
Testagen cycles are often paired with Epitalon, the master pineal bioregulator, twice yearly per Khavinson cycling convention.
Prostate/reproductive bioregulator combination
Male reproductive and prostate tissue support
Community interaction data label Testagen and Prostamax as synergistic within the male reproductive bioregulator set.
SERM adjunct (redundant caution)
Endogenous testosterone support
Listed as synergistic in community data, but both aim to raise endogenous testosterone, so the combination is likely redundant and may obscure which agent drives observed changes; not for early cycles.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Active prostate cancer
- Elevated PSA under investigation (e.g. above 4.0 ng/mL without a biopsy-confirmed benign explanation)
- Personal history of male breast cancer
- Known hypersensitivity to short-peptide bioregulators or capsule excipients (milk-protein isolates, starch)
- Concurrent anabolic-androgenic steroid use (suppressed HPG axis leaves no upstream signal to amplify)
- Adolescents and adults under 25
- Relative: PSA gray zone (2.5-4.0 ng/mL) without recent urology evaluation, hematocrit above 52%, untreated obstructive sleep apnea, untreated severe hypertension, active azoospermia under workup, active thromboembolic/thrombophilic history, advanced liver or kidney disease
Published Khavinson-group work describes Testagen as well tolerated, but trials are small (tens of patients), short (weeks to months), and rarely placebo-controlled, so 'well tolerated' is a provisional claim. Rare adverse events requiring thousands of patient-years to detect would not be visible. Theoretical long-term concerns include prostate tumor promotion in men with undiagnosed cancer, erythrocytosis, sleep-apnea worsening, and estradiol-related symptoms. Baseline PSA/DRE (age 45+), CBC, and periodic hormone panels are advised; long-term safety beyond two years of repeated cycling is undocumented.
FAQ
Testagen — common questions
What is Testagen?
Testagen is a short synthetic peptide bioregulator from Vladimir Khavinson's laboratory, marketed as an oral capsule for male reproductive support. It is the testicular-targeted member of the Khavinson family (male counterpart to Ovagen), proposed to enter testicular cell nuclei and modulate age-related gene expression in Leydig and Sertoli cells and the HPG axis.
Is Testagen a replacement for TRT?
No. TRT has decades of randomized controlled trials, global regulatory approval, and large safety datasets, and reliably raises testosterone several-fold with meaningful symptom improvement. Testagen at best produces a modest ~15-30% rise in small open-label observations, has no Western approval, and no large-scale safety data. It is at most a weak adjunct for the subclinical gray zone or for men who have declined standard therapy.
What is the standard Testagen cycle and dose?
The Khavinson-framework cycle is 1-2 oral capsules (20 mg nominal, ~2-4 mg peptide each) daily for 10 consecutive days, taken on an empty stomach in the morning, followed by a 60-90 day washout. The typical cadence is 2-4 cycles per year. Doses beyond 2 capsules daily are not supported by published data.
Does Testagen actually raise testosterone?
Published Khavinson-group observations suggest a modest ~15-30% rise in total testosterone in older men with borderline-low levels, but these are small, single-center, open-label studies without placebo controls. In absolute terms that is a small change (e.g. 350 to 420 ng/dL) that may or may not produce symptomatic benefit, and it is weak compared with TRT.
Can Testagen help with male infertility?
The evidence is thin. Khavinson-group data include modest, inconsistent observations of improved semen parameters, not randomized trials. A man trying to conceive should pursue reproductive urology workup, semen analyses, hormonal panels, and evidence-based options (varicocelectomy, clomiphene/enclomiphene, hCG, micronutrient optimization) before considering Testagen as a late-stack adjunct.
Is Testagen the same compound as Vesugen?
Some sources report both Testagen and Vesugen as identical Lys-Glu-Asp tripeptides, in which case mass spectrometry alone cannot distinguish them and the different proposed tissue targets are attributed to context-dependent effects. Other sources list Testagen as a Lys-Glu-Asp-Phe tetrapeptide. Buyers should be aware of this sequence ambiguity when purchasing.
Is Testagen legal and FDA-approved?
Testagen is not approved by the FDA, EMA, or any major Western regulator and has not undergone Phase 1-3 trials. It is legal to purchase as a research chemical for laboratory use in most jurisdictions but is not approved for human consumption in the US, EU, or most Western markets. No active FDA approval pathway exists.
How long until effects appear?
Subjective changes in energy, libido, or mood may be reported within the 10-day cycle, consolidating over the following 30 days. Biochemical changes are measured 2-6 weeks post-cycle (labs at 30-45 days). Semen-parameter changes, if any, require at least 3 months given the ~74-day spermatogenesis cycle. Users with no change after 2-3 documented cycles should redirect to evidence-based alternatives.
